- Home
- CSTL vs GMRE Comparison
CSTL vs GMRE Comparison
Compare CSTL & GMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- GMRE
- Stock Information
- Founded
- CSTL 2007
- GMRE 2011
- Country
- CSTL United States
- GMRE United States
- Employees
- CSTL 784
- GMRE N/A
- Industry
- CSTL Medical Specialities
- GMRE Real Estate Investment Trusts
- Sector
- CSTL Health Care
- GMRE Real Estate
- Exchange
- CSTL Nasdaq
- GMRE Nasdaq
- Market Cap
- CSTL 456.2M
- GMRE 485.5M
- IPO Year
- CSTL 2019
- GMRE N/A
- Fundamental
- Price
- CSTL $15.95
- GMRE $6.36
- Analyst Decision
- CSTL Strong Buy
- GMRE Buy
- Analyst Count
- CSTL 6
- GMRE 3
- Target Price
- CSTL $37.67
- GMRE $10.38
- AVG Volume (30 Days)
- CSTL 527.3K
- GMRE 682.5K
- Earning Date
- CSTL 05-05-2025
- GMRE 05-07-2025
- Dividend Yield
- CSTL N/A
- GMRE 12.26%
- EPS Growth
- CSTL N/A
- GMRE N/A
- EPS
- CSTL N/A
- GMRE 0.03
- Revenue
- CSTL $347,083,000.00
- GMRE $138,220,000.00
- Revenue This Year
- CSTL N/A
- GMRE $4.48
- Revenue Next Year
- CSTL $1.80
- GMRE $4.57
- P/E Ratio
- CSTL N/A
- GMRE $198.69
- Revenue Growth
- CSTL 38.43
- GMRE N/A
- 52 Week Low
- CSTL $15.45
- GMRE $6.06
- 52 Week High
- CSTL $35.84
- GMRE $10.46
- Technical
- Relative Strength Index (RSI)
- CSTL 33.63
- GMRE 31.83
- Support Level
- CSTL $15.45
- GMRE $6.16
- Resistance Level
- CSTL $16.43
- GMRE $6.42
- Average True Range (ATR)
- CSTL 0.59
- GMRE 0.18
- MACD
- CSTL 0.04
- GMRE -0.01
- Stochastic Oscillator
- CSTL 15.93
- GMRE 30.46
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.